ScholarLens Back to search
2002•Value in HealthRequires access

PCN12 IMPACT OF INNOVATIVE AND EXPENSIVE THERAPIES IN THE TREATMENT OF METASTATIC BREAST CANCER (MBC): FOCUS ON TRASTUZUMAB (HERCEPTIN(H))

H Miadi-Fargier, V. Trillet-Lenoir, Christell Ganne, Sandrine Couray‐Targe, Cyrille Colin

Open publisher page 1 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Trastuzumab, Metastatic breast cancer, Medicine, Oncology, Breast cancer, Internal medicine, Cancer

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
PCN12 IMPACT OF INNOVATIVE AND EXPENSIVE THERAPIES IN THE TREATMENT OF METASTATIC BREAST CANCER (MBC): FOCUS ON TRASTUZUMAB (HERCEPTIN(H)) — Research Paper | ScholarLens